10:26 AM EST, 11/17/2025 (MT Newswires) -- Solid Biosciences ( SLDB ) said Monday it has entered into a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences for the use of Solid's capsid AAV-SLB101.

Solid said it grants Andelyn a license to provide its gene therapy clients with access to utilize the capsid in combination with Andelyn's suspension and adherent modular platform process.

Financial terms of the agreement were not disclosed.

Andelyn is a cell and gene therapy contract development and manufacturing organization. AAV-SLB101 is developed for enhanced skeletal muscle and cardiac tropism and reduced biodistribution to the liver, Solid said.

Shares were up about 6% in recent trading.

Price: 4.50, Change: +0.26, Percent Change: +6.13